Intact Genomics (IG®) will participate in the 2025 Stanford Drug Discovery Symposium, which will take place April 28–29 at Stanford University. The prestigious event brings together leading researchers, biotech innovators, and pharmaceutical executives to discuss groundbreaking advancements in drug discovery and development.
Representatives from Intact Genomics, a growing leader in molecular biology reagents and point-of-care diagnostics, are engaging with top scientists and industry partners during the two-day symposium. The company is showcasing its latest innovations, including its newly developed and launched Direct Capture of Large Intact Genomic DNA technologies (DCLD™ technologies), RPA kits, PEmax Enzyme, and other molecular diagnostic and gene-editing solutions designed to accelerate gene function studies and drug discovery workflows.
“Our mission is to empower researchers with the tools they need to drive scientific breakthroughs,” said Dr. Charles Wu, CEO of Intact Genomics. “Being part of the Stanford Drug Discovery Symposium is a tremendous opportunity for us to connect with the global scientific community and contribute to conversations that shape the future of medicine.”
This year’s symposium features keynote speeches by Nobel laureates, presentations on AI in drug discovery, advances in targeted therapeutics, and panels on the future of personalized medicine. Intact Genomics’ presence highlights its commitment to supporting innovation and collaboration across the life sciences industry.